Evidence map›Paper›PMID 36505881›Full record

ArticleFrontiers in oncology2022

Underlying reasons for post-mortem diagnosed lung cancer cases - A robust retrospective comparative study from Hungary (HULC study).

Zolta N Kiss, Krisztina Bogos, Lilla Tamási, Gyula Ostoros, Veronika Müller, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Kata Knollmajer, Máté Várnai and 20 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 7 institutions in 2 countries.

Zolta N KissMSD Pharma Hungary Ltd, Budapest, Hungary.
Krisztina BogosNational Korányi Institute of Pulmonology, Directorate of Institution, Budapest, Hungary.
Lilla TamásiDepartment of Pulmonology, Semmelweis University, Budapest, Hungary.
Gyula OstorosNational Korányi Institute of Pulmonology, Directorate of Institution, Budapest, Hungary.
Veronika MüllerDepartment of Pulmonology, Semmelweis University, Budapest, Hungary.
Nóra BittnerDepartment of Pulmonology, University of Debrecen, Debrecen, Hungary.
Veronika SárosiFaculty of Medicine, University of Pécs, Pécs, Hungary.
Aladár VastagMSD Pharma Hungary Ltd, Budapest, Hungary.
Kata KnollmajerMSD Pharma Hungary Ltd, Budapest, Hungary.
Máté VárnaiMSD Pharma Hungary Ltd, Budapest, Hungary.
Krisztina KovácsMSD Pharma Hungary Ltd, Budapest, Hungary.
Andrea BertaMSD Pharma Hungary Ltd, Budapest, Hungary.
István KöveskutiMSD Pharma Hungary Ltd, Budapest, Hungary.
Eugenia KaramousouliMSD Pharma Hungary Ltd, Budapest, Hungary.
György RokszinRxTarget Ltd., Szolnok, Hungary.
Zsolt Abonyi-TóthRxTarget Ltd., Szolnok, Hungary.
Zsófia BarczaSyntesia Medical Communications Ltd, Budapest, Hungary.
István Kenessey1st Department of Pulmonology, National Korányi Institute of Pulmonology, Semmelweis University, Budapest, Hungary.
András WeberNational Institute of Oncology, National Tumorbiology Laboratory project (NLP-17), Budapest, Hungary.
Péter NagyNational Institute of Oncology, National Tumorbiology Laboratory project (NLP-17), Budapest, Hungary.
Petra Freyler-FadgyasNational Health Insurance Fund, Department of Project Management and Data Services, Budapest, Hungary.
Miklós SzócskaInstitute of Digital Health Sciences, Semmelweis University, Budapest, Hungary.
Péter SzegnerInstitute of Digital Health Sciences, Semmelweis University, Budapest, Hungary.
Lászlóné HilbertHungarian Central Statistical Office, Department of Population Statistics, Budapest, Hungary.
Gabriella Branyiczkiné GéczyHungarian Central Statistical Office, Department of Population Statistics, Budapest, Hungary.
György SurjánInstitute of Digital Health Sciences, Semmelweis University, Budapest, Hungary.
Judit Moldvay2nd Department of Pathology, MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary.
Zoltán VokóCenter for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Gabriella GálffyPulmonology Hospital Törökbálint, 6th Department, Törökbálint, Hungary.
Zoltán PolányiMSD Pharma Hungary Ltd, Budapest, Hungary.
Semmelweis University · HUOrszágos Korányi Tbc és Pulmonológiai Intézet · HUHungarian Central Statistical Office · HUUniversity of Debrecen · HUCentre International de Recherche sur le Cancer · FRUniversity of Pecs · HUUniversity of Veterinary Medicine · HU

Funding

World Health Organization 001
6 · The paper itself

Abstract

Objective: The Hungarian Undiagnosed Lung Cancer (HULC) study aimed to explore the potential reasons for missed LC (lung cancer) diagnosis by comparing healthcare and socio-economic data among patients with post-mortem diagnosed LC with those who were diagnosed with LC during their lives. Methods: This nationwide, retrospective study used the databases of the Hungarian Central Statistical Office (HCSO) and National Health Insurance Fund (NHIF) to identify patients who died between January 1, 2019 and December 31, 2019 and were diagnosed with lung cancer post-mortem (population A) or during their lifetime (population B). Patient characteristics, socio-economic factors, and healthcare resource utilization (HCRU) data were compared between the diagnosed and undiagnosed patient population. Results: During the study period, 8,435 patients were identified from the HCSO database with LC as the cause of death, of whom 1,203 (14.24%) had no LC-related ICD (International Classification of Diseases) code records in the NHIF database during their lives (post-mortem diagnosed LC population). Post-mortem diagnosed LC patients were significantly older than patients diagnosed while still alive (mean age 71.20 vs. 68.69 years, p<0.001), with a more pronounced age difference among female patients (difference: 4.57 years, p<0.001), and had significantly fewer GP (General Practitioner) and specialist visits, X-ray and CT scans within 7 to 24 months and 6 months before death, although the differences in GP and specialist visits within 7-24 months did not seem clinically relevant. Patients diagnosed with LC while still alive were more likely to be married (47.62% vs. 33.49%), had higher educational attainment, and had more children, than patients diagnosed with LC post-mortem. Conclusions: Post-mortem diagnosed lung cancer accounts for 14.24% of total lung cancer mortality in Hungary. This study provides valuable insights into patient characteristics, socio-economic factors, and HCRU data potentially associated with a high risk of lung cancer misdiagnosis.

Indexed as

delayed diagnosislate stagelung cancerlung cancer mortalitypost-mortem diagnoses

Identifiers

PMID36505881
PMCPMC9732724
OpenAlexW4310039548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.